Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world

被引：0
|
作者：
Sugimoto, Chikatoshi
Inoue, Yoshikazu
Arai, Toru
Kasai, Takehiko
Akira, Masanori
Hayashi, Seiji
Tachibana, Kazunobu
Sasaki, Yumiko
Takeuchi, Naoko
Minomo, Syojiro
Ikegami, Naoya
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA4878
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4878
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
    De Biasi, Sara
    Cerri, Stefania
    Bianchini, Elena
    Gibellini, Lara
    Persiani, Elisa
    Montanari, Gloria
    Luppi, Fabrizio
    Carbonelli, Cristiano Matteo
    Zucchi, Luigi
    Bocchino, Marialuisa
    Zamparelli, Alessandro Sanduzzi
    Vancheri, Carlo
    Sgalla, Giacomo
    Richeldi, Luca
    Cossarizza, Andrea
    BMC MEDICINE, 2015, 13
  • [42] Missing out on effective care in idiopathic pulmonary fibrosis: Racial inequality in access to anti-fibrotic therapy
    Pascoe, Amy
    Smallwood, Natasha
    RESPIROLOGY, 2023, 28 (11) : 978 - 979
  • [43] SYSTEMIC ANTI-FIBROTIC EFFECTS OF PIRFENIDONE IN PRECLINICAL STUDIES AND CLINICAL ACTIVITY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Kossen, Karl
    Schaefer, C. J.
    Bradford, W. Z.
    Seiwert, S. D.
    INFLAMMATION RESEARCH, 2012, 61 : S5 - S5
  • [44] WEIGHT LOSS HAS A SIGNIFICANT IMPACT ON ANTI-FIBROTIC DRUG TOLERANCE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Moon, R. D. C.
    Barker, E.
    Agnew, S.
    Sutcliffe, J.
    Kwok, A.
    Spencer, L. G.
    THORAX, 2017, 72 : A250 - A250
  • [45] Anti-Fibrotic Role Of Inhaled Interferon-γ Detected By Proteomic Studies In Patients With Idiopathic Pulmonary Fibrosis
    Hasaneen, N. A.
    Haley, J.
    Foda, H. D.
    Condos, R.
    Smaldone, G. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [46] Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
    Takumi Yoshikawa
    Mitsuo Otsuka
    Hirofumi Chiba
    Kimiyuki Ikeda
    Yuki Mori
    Yasuaki Umeda
    Hirotaka Nishikiori
    Koji Kuronuma
    Hiroki Takahashi
    BMC Pulmonary Medicine, 20
  • [47] PULMONARY HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ON ANTI-FIBROTIC TREATMENT WITH PIRFENIDONE OR NINTEDANIB: CLINICAL EVALUATION AND PROGNOSTIC IMPACT
    Stornelli, Silvia Romana
    Lacedonia, Donato
    Scioscia, Giulia
    Simone, Filomena
    Lepore, Giorgia
    Sabato, Roberto
    Giganti, Giulio
    Ciliberti, Gianluca
    Barbaro, Maria Pia Foschino
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [48] ELIGIBILITY FOR ANTI-FIBROTIC TREATMENT IN IDIOPATHIC PULMONARY FIBROSIS (IPF) DEPENDS ON THE PREDICTIVE EQUATION USED IN PULMONARY FUNCTION TESTING
    Burgess, Andrew
    Goon, Ken
    Attia, John
    Palazzi, Kerrin
    Brannan, John
    Grainge, Christopher
    RESPIROLOGY, 2017, 22 : 46 - 46
  • [49] The Anti-Fibrotic Role Of Plexin C1 In Pulmonary Fibrosis
    Moore, M. W.
    Mathur, A.
    Gan, Y.
    Herzog, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [50] The Anti-Fibrotic Role Of Plexin C1 In Pulmonary Fibrosis
    Mathur, A.
    Moore, M.
    Gan, Y.
    Zhou, Y.
    Peng, X.
    Herzog, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
12345